Citations (31)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Jeremy M. Shefner, Jinsy A. Andrews, Angela Genge, Carlayne Jackson, Noah Lechtzin, Timothy M. Miller, Bettina M. Cockroft, Lisa Meng, Jenny Wei, Andrew A. Wolff, Fady I. Malik, Cynthia Bodkin, Benjamin R. Brooks, James Caress, Annie Dionne, Dominic Fee, Stephen A. Goutman, Namita A. Goyal, Orla Hardiman, Ghazala Hayat, Terry Heiman-Patterson, Daragh Heitzman, Robert D. Henderson, Wendy Johnston, Chafic Karam, Matthew C. Kiernan, Stephen J. Kolb, Lawrence Korngut, Shafeeq Ladha, Genevieve Matte, Jesus S. Mora, Merrilee Needham, Bjorn Oskarsson, Gary L. Pattee, Erik P. Pioro, Michael Pulley, Dianna Quan, Kourosh Rezania, Kerri L. Schellenberg, David Schultz, Christen Shoesmith, Zachary Simmons, Jeffrey Statland, Shumaila Sultan, Andrea Swenson, Leonard H. Van Den Berg, Tuan Vu, Steve Vucic, Michael Weiss, Ashley Whyte-Rayson, James Wymer, Lorne Zinman & Stacy A. Rudnicki. (2021) A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of Reldesemtiv In Patients With ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 22:3-4, pages 287-299.
Read now
Read now
Jinsy A. Andrews, Merit E. Cudkowicz, Orla Hardiman, Lisa Meng, Amy Bian, Jacqueline Lee, Andrew A. Wolff, Fady I. Malik & Jeremy M. Shefner. (2018) VITALITY-ALS, a phase III trial of tirasemtiv, a selective fast skeletal muscle troponin activator, as a potential treatment for patients with amyotrophic lateral sclerosis: study design and baseline characteristics. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 19:3-4, pages 259-266.
Read now
Read now
Jeremy M. Shefner, Andrew A. Wolff, Lisa Meng, Amy Bian, Jacqueline Lee, Donna Barragan & Jinsy A. Andrews. (2016) A randomized, placebo-controlled, double-blind phase IIb trial evaluating the safety and efficacy of tirasemtiv in patients with amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 17:5-6, pages 426-435.
Read now
Read now
Jeremy M. Shefner & Dragos Mihaila. (2014) Assessment of disease progression and functional benefit in neurodegenerative disease: Can we tell the difference?. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 15:5-6, pages 337-343.
Read now
Read now
Jeremy M. Shefner, Mary Lou Watson, Lisa Meng & Andrew A. Wolff. (2013) A study to evaluate safety and tolerability of repeated doses of tirasemtiv in patients with amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 14:7-8, pages 574-581.
Read now
Read now
Jeremy M. Shefner, Andrew A. Wolff & Lisa Meng. (2013) The relationship between tirasemtiv serum concentration and functional outcomes in patients with ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 14:7-8, pages 582-585.
Read now
Read now
Paul Gordon, Philippe Corcia & Vincent Meininger. (2013) New therapy options for amyotrophic lateral sclerosis. Expert Opinion on Pharmacotherapy 14:14, pages 1907-1917.
Read now
Read now
Michael P Bova & Gene G Kinney. (2013) Emerging drug targets in amyotrophic lateral sclerosis. Expert Opinion on Orphan Drugs 1:1, pages 5-20.
Read now
Read now
Articles from other publishers (23)
Wout J. Claassen, Rianne J. Baelde, Ricardo A. Galli, Josine M. de Winter & Coen A. C. Ottenheijm. (2023) Small molecule drugs to improve sarcomere function in those with acquired and inherited myopathies. American Journal of Physiology-Cell Physiology 325:1, pages C60-C68.
Crossref
Crossref
Tereza Filipi, Zuzana Hermanova, Jana Tureckova, Ondrej Vanatko & Miroslava Anderova. (2020) Glial Cells—The Strategic Targets in Amyotrophic Lateral Sclerosis Treatment. Journal of Clinical Medicine 9:1, pages 261.
Crossref
Crossref
Leo H. Wang & Michael D. Weiss. (2018) A muscle strength enhancer for all seasons?. Muscle & Nerve 57:5, pages 697-698.
Crossref
Crossref
Scott E. Collibee, Gustave Bergnes, Alexander Muci, William F. BrowneIVIV, Marc Garard, Aaron C. Hinken, Alan J. Russell, Ion Suehiro, James Hartman, Raja Kawas, Pu-Ping Lu, Kenneth H. Lee, David Marquez, Matthew Tomlinson, Donghong Xu, Adam Kennedy, Darren Hwee, Julia Schaletzky, Kwan Leung, Fady I. Malik, David J. MorgansJr.Jr. & Bradley P. Morgan. (2018)
Discovery of
Tirasemtiv
, the First Direct Fast Skeletal Muscle Troponin Activator
. ACS Medicinal Chemistry Letters 9:4, pages 354-358.
Crossref
Crossref
Mathieu Gruet, Thierry Troosters & Samuel Verges. (2017) Peripheral muscle abnormalities in cystic fibrosis: Etiology, clinical implications and response to therapeutic interventions. Journal of Cystic Fibrosis 16:5, pages 538-552.
Crossref
Crossref
Marco L. AlvesChad M. WarrenJillian N. SimonRobert D. GaffinEric M. MontminyDavid F. WieczorekR. John SolaroBeata M. Wolska. (2017) Early sensitization of myofilaments to Ca2+ prevents genetically linked dilated cardiomyopathy in mice. Cardiovascular Research 113:8, pages 915-925.
Crossref
Crossref
Richard Smith, Erik Pioro, Kathleen Myers, Michael Sirdofsky, Kimberly Goslin, Gregg Meekins, Hong Yu, James Wymer, Merit Cudkowicz, Eric A. Macklin, David Schoenfeld & Gary Pattee. (2017) Enhanced Bulbar Function in Amyotrophic Lateral Sclerosis: The Nuedexta Treatment Trial. Neurotherapeutics 14:3, pages 762-772.
Crossref
Crossref
Josine M. de Winter & Coen A.C. Ottenheijm. (2017) Sarcomere Dysfunction in Nemaline Myopathy. Journal of Neuromuscular Diseases 4:2, pages 99-113.
Crossref
Crossref
Dmitry Petrov, Colin Mansfield, Alain Moussy & Olivier Hermine. (2017) ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment?. Frontiers in Aging Neuroscience 9.
Crossref
Crossref
Darren T. Hwee, Arthur J. Cheng, James J. Hartman, Aaron C. Hinken, Ken Lee, Nickie Durham, Alan J. Russell, Fady I. Malik, Håkan Westerblad & Jeffrey R. Jasper. (2017)
The Ca
2+
sensitizer CK-2066260 increases myofibrillar Ca
2+
sensitivity and submaximal force selectively in fast skeletal muscle
. The Journal of Physiology 595:5, pages 1657-1670.
Crossref
Crossref
Jeremy M. Shefner. (2016) Strength Testing in Motor Neuron Diseases. Neurotherapeutics 14:1, pages 154-160.
Crossref
Crossref
Jean‐Philippe Loeffler, Gina Picchiarelli, Luc Dupuis & Jose‐Luis Gonzalez De Aguilar. (2016) The Role of Skeletal Muscle in Amyotrophic Lateral Sclerosis. Brain Pathology 26:2, pages 227-236.
Crossref
Crossref
Darren T. Hwee, Adam R. Kennedy, James J. Hartman, Julie Ryans, Nickie Durham, Fady I. Malik & Jeffrey R. Jasper. (2015) The Small-Molecule Fast Skeletal Troponin Activator, CK-2127107, Improves Exercise Tolerance in a Rat Model of Heart Failure. Journal of Pharmacology and Experimental Therapeutics 353:1, pages 159-168.
Crossref
Crossref
Donald B. Sanders, Jeffrey Rosenfeld, Mazen M. Dimachkie, Lisa Meng & Fady I. Malik. (2015) A Double-Blinded, Randomized, Placebo-Controlled Trial to Evaluate Efficacy, Safety, and Tolerability of Single Doses of Tirasemtiv in Patients with Acetylcholine Receptor-Binding Antibody-Positive Myasthenia Gravis. Neurotherapeutics 12:2, pages 455-460.
Crossref
Crossref
Nam-Hee KimMin Oh Lee. (2015) Update of Therapeutic Clinical Trials for Amyotrophic Lateral Sclerosis. Korean Journal of Clinical Neurophysiology 17:1, pages 1.
Crossref
Crossref
Richard Hansen, Khalil G. Saikali, Willis Chou, Alan J. Russell, Michael M. Chen, Vipin Vijayakumar, Randall R. Stoltz, Stephane Baudry, Roger M. Enoka, David J. Morgans, Andrew A. Wolff & Fady I. Malik. (2014) Tirasemtiv amplifies skeletal muscle response to nerve activation in humans. Muscle & Nerve 50:6, pages 925-931.
Crossref
Crossref
Timothy A Bauer, Andrew A Wolff, Alan T Hirsch, Lisa L Meng, Kevin Rogers, Fady I Malik & William R Hiatt. (2014) Effect of tirasemtiv, a selective activator of the fast skeletal muscle troponin complex, in patients with peripheral artery disease. Vascular Medicine 19:4, pages 297-306.
Crossref
Crossref
Darren T. Hwee, Adam Kennedy, Julie Ryans, Alan J. Russell, Zhiheng Jia, Aaron C. Hinken, David J. Morgans, Fady I. Malik & Jeffrey R. Jasper. (2014) Fast Skeletal Muscle Troponin Activator tirasemtiv Increases Muscle Function and Performance in the B6SJL-SOD1G93A ALS Mouse Model. PLoS ONE 9:5, pages e96921.
Crossref
Crossref
Nicole L. Nichols, J. Van Dyke, L. Nashold, I. Satriotomo, M. Suzuki & G.S. Mitchell. (2013) Ventilatory control in ALS. Respiratory Physiology & Neurobiology 189:2, pages 429-437.
Crossref
Crossref
Marie Amitani, Akihiro Asakawa, Haruka Amitani & Akio Inui. (2013) Control of food intake and muscle wasting in cachexia. The International Journal of Biochemistry & Cell Biology 45:10, pages 2179-2185.
Crossref
Crossref
Jessica J. Miciak, Leigh C. Warsing, Maria E. Tibbs, Jeffrey R. JASPER, Sarah B. Jampel, Fady I. Malik, Clarke Tankersley & Kathryn R. Wagner. (2013) Fast skeletal muscle troponin activator in the dy2J muscular dystrophy model. Muscle & Nerve 48:2, pages 279-285.
Crossref
Crossref
Josine Marieke de Winter, Danielle Buck, Carlos Hidalgo, Jeffrey R Jasper, Fady I Malik, Nigel F Clarke, Ger J M Stienen, Michael W Lawlor, Alan H Beggs, Coen A C Ottenheijm & Henk Granzier. (2013) Troponin activator augments muscle force in nemaline myopathy patients with nebulin mutations. Journal of Medical Genetics 50:6, pages 383-392.
Crossref
Crossref
Coen A. C. Ottenheijm, Danielle Buck, Josine M. de Winter, Claudia Ferrara, Nicoletta Piroddi, Chiara Tesi, Jeffrey R. Jasper, Fady I. Malik, Hui Meng, Ger J. M. Stienen, Alan H. Beggs, Siegfried Labeit, Corrado Poggesi, Michael W. Lawlor & Henk Granzier. (2013) Deleting exon 55 from the nebulin gene induces severe muscle weakness in a mouse model for nemaline myopathy. Brain 136:6, pages 1718-1731.
Crossref
Crossref